AIIMS to conduct human trials of Covaxin


The All India Institute of Medical Science (AIIMS) Ethics Committee approved for a human clinical trial of the COVID-19 vaccine Covaxin following which the hospital will start testing on healthy volunteers from Monday onwards.

AIIMS-Delhi is among the 12 places selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin. In phase I, the vaccine would be tested on 375 volunteers and a maximum of 100 of them would be from AIIMS.

” Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial,” Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS said.

COVID-19 vaccine Covaxin was developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology. It received approval for human clinical trials from the Drugs Controller General of India.

You might also like